Age: 46 President Since 2012
The company has return on total asset (ROA) of 14.17 % which means that it generated profit of $14.17 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.9 % meaning that it created $23.9 on every $100 dollars invested by stockholders.
The company currently holds 595.93 M in liabilities with Debt to Equity (D/E) ratio of 0.07 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 1.77 which is within standard range for the sector.
Entity SummaryBiogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 6,850 people.
Filter other executives
Biogen Idec IncUSA StockCurrency: USD - US DollarTraded on NASDAQ
Fix Your Portfolios with Biogen
Promote Biogen and Gregory Covino
Biogen Idec Leadership
Use alpha and beta coefficients to find investment opportunities after accounting for the riskFind Alpha
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and familiesResearch Equities
Find insiders across different sectors to evaluate their impact on performance and growth of their entitiesResearch Insiders